How does the anti-Müllerian hormone (AMH) cutoff of 3.2 ng/mL perform in diagnosing polycystic ovarian morphology (PCOM) in young adult women 18-24 years of age? At the cutoff of 3.2 ng/mL using Elecsys AMH Plus immunoassay, AMH shows a high sensitivity and specificity in identifying PCOM in young adult women. Polycystic ovary syndrome (PCOS) is diagnosed using the Rotterdam criteria with at least two out of three criteria being met: oligo-anovulation (OA), hyperandrogenism (HA) and PCOM. The diagnosis of PCOM is using either antral follicle count (AFC) or AMH. The Roche Elecsys AMH Plus immunoassay was validated at a cutoff of 3.2 ng/mL for detecting PCOM as part of the PCOS diagnosis in 25-45 year old women. This was a retrospective case-control study conducted between October 2024 and December 2024. The study used banked samples from 136 women with PCOS and 85 controls in the age range 18-24 years. The PCOS cases were defined by Rotterdam criteria fulfilling at least 2 out of 3 diagnostic criteria (OA, HA and PCOM), and the control women were healthy subjects with an AFC of < 20 antral follicles/ovary. Serum levels of AMH were measured using the Roche Elecsys® AMH Plus immunoassay, AFC was determined using transvaginal ultrasound. The performance of the AMH cutoff of 3.2 ng/mL to distinguish between PCOM cases using PCOS phenotype A (OA+HA+PCOM) and strict controls (primary population) was assessed. As sensitivity analysis the performance of the cutoff was assessed in a cohort consisting of the PCOS phenotypes with PCOM (OA+HA+PCOM, OA+PCOM, HA+PCOM) and strict controls. In the primary population, women with PCOS (cases) and healthy women (controls) were similar in age (median age 21.0 vs 22.0 years) and body mass index (median BMI 23.8 vs 22.0 kg/m2). At the previously established cut off of 3.2 ng/mL the Elecsys AMH Plus immunoassay showed 85.0 % sensitivity (95% confidence interval [CI]: 76.5–91.4%) and 68.2% specificity (95% CI: 57.2–77.9%) for detecting PCOM in the primary population that consisted of women aged 18-24 years with the full blown PCOS (OA+HA+PCOM) and healthy controls. The overall percentage agreement (OPA) in this population was 77.3% (95% CI: 70.6-83.1%) and the area under the receiver operating characteristic curve (AUC-ROC) for the prediction of case-control status by serum AMH was 85.8% (95% CI: 80.5–91.0%). When all phenotypes with PCOM (OA+HA+PCOM; OA+PCOM; HA+PCOM) were included the sensitivity was 83.5% (95% CI: 76.0-89.3%) and the specificity 68.2% (95% CI 57.2-77.9%). OPA was 77.5% (95% CI 71.4-82.9%) and AUC-ROC was found to be 84.6% (95% CI 79.5-89.6%) including all phenotypes with PCOM. The Spearman correlation coefficient between AMH and AFC found in the full study population, was 0.70. The study design was a case-control study in a cohort with control women being healthy without any symptoms of PCOS. Therefore, the AMH cutoff of 3.2 ng/mL needs to be further validated in independent cohort study in young adult women with suspected PCOS. The Roche Elecsys AMH Plus immunoassay is a useful and robust method for identifying PCOM as part of the PCOS diagnosis in conjunction with other clinical characteristics defined by the Rotterdam criteria in young women in the age range from 18 to 24 years. No
Студент ВО, Гладких ФВ, Лядова ТІ, Матвєєнко МС. Біотехнологічна модуляція системи вільнорадикального окиснення розглядається при токсичному ураженні печінки, індукованому німесулідом. Матеріали науково-практичної конференції з міжнародною участю «Бабенківські читання» присвячена: пам’яті академіка Г.О. Бабенка, 80-річчю Івано-Франківського національного медичного університету; 2025 Жовтень 30–31; Івано-Франківськ: Івано-Франківський національний медичний університет МОЗ України; 2025, с. 169–170. DOI: https://doi.org/10.5281/zenodo.17644582
